Moreover, the anticancer efficacy of the antifungal itraconazole, which also inhibits NPC1 and is being repurposed in clinical trials for several cancers (see Section 3.1 and Table 2), could be potentiated by its ability to bind and inhibit the OSBP- and ORP4-mediated exchange of cholesterol and phosphatidylinositol-4-phosphate. This evidence concerns the gene OSBP2 and cancer.